Study: NCT06195228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib plus trametinib with or without PD-1 antibody
Description: advanced thyroid cancer patients who harbor BRAF V600E mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor NTRK mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
Description: advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown